Evidence map›Paper›PMID 34916002›Full record

ReviewSeminars in nephrology2021

Plasma and Urine Biomarkers of CKD: A Review of Findings in the CKiD Study.

Ibrahim Sandokji, Jason H Greenberg

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Seminars in nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00327860 (Chronic Kidney Disease in Children Prospective Cohort Study), which is not on this map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00327860 recruitingnot on this map

Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)

TypeobservationalSponsorJohns Hopkins Bloomberg School of Public HealthRan2003 to 2028Enrolled1,300ConditionsChronic Kidney Disease
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Urinary extracellular vesicles in childhood kidney diseases.Pediatric nephrology (Berlin, Germany) · 2024
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Ibrahim SandokjiSection of Nephrology, Clinical and Translational Research Accelerator, Department of Pediatrics, Yale University School of Medicine, New Haven, CT; Department of Pediatrics, Taibah University College of Medicine, Medina, Saudi Arabia.
Jason H GreenbergSection of Nephrology, Clinical and Translational Research Accelerator, Department of Pediatrics, Yale University School of Medicine, New Haven, CT. Electronic address: jason.greenberg@yale.edu.
Taibah University · SAYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
CKiD Cardiovascular Testing Travel SupplementU01DK066143 · NIDDK · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · PI Bradley Alan Warady · 2003 to 2026
$24.2M
The Kidney Disease in Children Data Management and Analysis Center (KIDMAC)U24DK066116 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI Derek K Ng · 2018 to 2026
$12.6M
Novel Biomarkers of Chronic Kidney Disease in ChildrenK08DK110536 · NIDDK · YALE UNIVERSITY · PI GREENBERG, JASON HENRY · 2016 to 2021
$882k
NCATS NIH HHS UL1 TR001863NIDDK NIH HHS K08 DK110536NIDDK NIH HHS L40 DK110937NIDDK NIH HHS U01 DK066143NIDDK NIH HHS U24 DK066116
6 · The paper itself

Abstract

Serum creatinine and level of proteinuria, as biomarkers of chronic kidney disease (CKD) progression, inadequately explain the variability of glomerular filtration rate decline, and are late markers of glomerular filtration rate decline. Recent studies have identified plasma and urine biomarkers at higher levels in children with CKD and also associate independently with CKD progression, even after adjustment for serum creatinine and proteinuria. These novel biomarkers represent diverse biologic pathways of tubular injury, tubular dysfunction, inflammation, and tubular health, and can be used as a liquid biopsy to better characterize CKD in children. In this review, we highlight the biomarker findings from the Chronic Kidney Disease in Children cohort, a large longitudinal study of children with CKD, and compare results with those from other pediatric CKD cohorts. The biomarkers in focus in this review include plasma kidney injury molecule-1, monocyte chemoattractant protein-1, fibroblast growth factor-23, tumor necrosis factor receptor-1, tumor necrosis factor receptor-2, soluble urokinase plasminogen activator receptor, and chitinase-3-like protein 1, as well as urine epidermal growth factor, α-1 microglobulin, kidney injury molecule-1, monocyte chemoattractant protein-1, and chitinase-3-like protein 1. Blood and urine biomarkers improve our ability to prognosticate CKD progression and may improve our understanding of CKD pathophysiology. Further research is required to establish how these biomarkers can be used in the clinical setting to improve the clinical management of CKD.

Indexed as

Chemokine CCL2Renal Insufficiency, ChronicBiomarkersChildChitinase-3-Like Protein 1CreatinineDisease ProgressionFemaleGlomerular Filtration RateHumansLongitudinal StudiesMaleProteinuriaBiomarkersChemokine CCL2Chitinase-3-Like Protein 1CreatinineBiomarkerchronic kidney diseaseCKD progressionend-stage kidney diseasekidney injurypediatrics

Identifiers

PMID34916002
PMCPMC8694618
OpenAlexW4200120173

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.